• Publications
  • Influence
Beyond the margins: real-time detection of cancer using targeted fluorophores
Over the past two decades, synergistic innovations in imaging technology have resulted in a revolution in which a range of biomedical applications are now benefiting from fluorescence imaging.Expand
  • 148
  • 3
Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy
Tumor-specific alkylphosphocholine analogs were evaluated as imaging and therapy agents in patients and in animal models of human cancer. A Broad View of Cancer Many consider targeted or molecularExpand
  • 53
  • 1
  • PDF
In Silico Docking of Alkylphosphocholine Analogs to Human Serum AlbuminPredict Partitioning and Pharmacokinetics.
Alkylphosphocholine (APC) analogs are a novel class of broad-spectrum tumor-targeting agents that can be used for both diagnosis and treatment of cancer. The potential for clinical translation forExpand
  • 3
  • 1
A Phase 1 Study of 131I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety
Introduction 131I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administeredExpand
  • 17
  • PDF
Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.
TLDR
This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry) that utilizes serial PET/CT or SPECT/CT images to calculate voxelized 3D internal dose distributions with the Monte Carlo code Geant4. Expand
  • 14
90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma
Finding improved therapeutic strategies against T-cell Non-Hodgkin’s Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targetingExpand
  • 8
Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502
Positive margins after breast conservation surgery represent a significant problem in the treatment of breast cancer. The near-infrared fluorescence agent CLR1502 (Cellectar Biosciences, Madison, WI)Expand
  • 5
Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.
Assessment of targeted radionuclide therapy (TRT) agent effectiveness based on its pharmacokinetic (PK) properties could provide means to expedited agent development or its rejection. A broad PKExpand
  • 8
The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.
Biologically effective dose (BED) may be more of a relevant quantity than absorbed dose for establishing tumour response relationships. By taking into account the dose rate and tissue-specificExpand
  • 7
Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation.
The efficacy of systemically administered radiopharmaceuticals depends on the physiological path of the targeting molecule and the physical characteristics of the attached radionuclide. NM404 is aExpand
  • 7